skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations

Abstract

Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 (223Ra) dichloride (Xofigo®) is the first α-emitter to have received FDA approval for the treatment of prostate cancer with metastatic bone lesions. There is a significant increase in the number of clinical trials in oncology using several radionuclides such as Actinium-225 (225Ac), Bismuth-213 (213Bi), Lead-212 (212Pb), Astatine (211At) or Radium-223 (223Ra) assessing their safety and preliminary activity. Finally, this review will cover their therapeutic application as well as summarize the investigations that provide the foundation for further clinical development.

Authors:
 [1];  [2];  [3];  [3];  [3];  [1];  [3];  [4];  [3];  [2];  [1]
  1. Univ. of New Mexico, Albuquerque, NM (United States). Radiopharmaceutical Sciences Program. College of Pharmacy. Health Sciences Center
  2. Univ. of New Mexico Comprehensive Cancer Center, Albuquerque, NM (United States). Experimental Therapeutics Unit
  3. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
  4. Univ. of New Mexico, Albuquerque, NM (United States). Radiopharmaceutical Sciences Program. College of Pharmacy. Health Sciences Center; Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Univ. of New Mexico, Albuquerque, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1459839
Report Number(s):
LA-UR-16-27976
Journal ID: ISSN 1776-2596
Grant/Contract Number:  
AC52-06NA25396
Resource Type:
Accepted Manuscript
Journal Name:
Targeted Oncology
Additional Journal Information:
Journal Volume: 13; Journal Issue: 2; Journal ID: ISSN 1776-2596
Publisher:
Springer
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE

Citation Formats

Makvandi, Mehran, Dupis, Edouard, Engle, Jonathan W., Nortier, F. Meiring, Fassbender, Michael E., Simon, Sam, Birnbaum, Eva R., Atcher, Robert W., John, Kevin D., Rixe, Olivier, and Norenberg, Jeffrey P. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. United States: N. p., 2018. Web. doi:10.1007/s11523-018-0550-9.
Makvandi, Mehran, Dupis, Edouard, Engle, Jonathan W., Nortier, F. Meiring, Fassbender, Michael E., Simon, Sam, Birnbaum, Eva R., Atcher, Robert W., John, Kevin D., Rixe, Olivier, & Norenberg, Jeffrey P. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. United States. doi:10.1007/s11523-018-0550-9.
Makvandi, Mehran, Dupis, Edouard, Engle, Jonathan W., Nortier, F. Meiring, Fassbender, Michael E., Simon, Sam, Birnbaum, Eva R., Atcher, Robert W., John, Kevin D., Rixe, Olivier, and Norenberg, Jeffrey P. Thu . "Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations". United States. doi:10.1007/s11523-018-0550-9. https://www.osti.gov/servlets/purl/1459839.
@article{osti_1459839,
title = {Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations},
author = {Makvandi, Mehran and Dupis, Edouard and Engle, Jonathan W. and Nortier, F. Meiring and Fassbender, Michael E. and Simon, Sam and Birnbaum, Eva R. and Atcher, Robert W. and John, Kevin D. and Rixe, Olivier and Norenberg, Jeffrey P.},
abstractNote = {Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 (223Ra) dichloride (Xofigo®) is the first α-emitter to have received FDA approval for the treatment of prostate cancer with metastatic bone lesions. There is a significant increase in the number of clinical trials in oncology using several radionuclides such as Actinium-225 (225Ac), Bismuth-213 (213Bi), Lead-212 (212Pb), Astatine (211At) or Radium-223 (223Ra) assessing their safety and preliminary activity. Finally, this review will cover their therapeutic application as well as summarize the investigations that provide the foundation for further clinical development.},
doi = {10.1007/s11523-018-0550-9},
journal = {Targeted Oncology},
number = 2,
volume = 13,
place = {United States},
year = {2018},
month = {2}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 8 works
Citation information provided by
Web of Science

Figures / Tables:

Fig. 1 Fig. 1 : Path length and ionization density of $α$-particles versus $β$-particles

Save / Share:

Works referenced in this record:

First Clinical Experience with  -Emitting Radium-223 in the Treatment of Skeletal Metastases
journal, June 2005


Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy
journal, January 2013


Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
journal, June 2008


Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia
journal, May 2014


Design and evaluation of an external high-current target for production of 211 At
journal, October 2012

  • Gagnon, K.; Risler, R.; Pal, S.
  • Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 55, Issue 12
  • DOI: 10.1002/jlcr.2968

Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization
journal, March 2007


Preliminary Production of 211At at the Texas A&M University Cyclotron Institute
journal, January 2014


225Ac-PSMA-617 for PSMA-Targeted  -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
journal, July 2016

  • Kratochwil, C.; Bruchertseifer, F.; Giesel, F. L.
  • Journal of Nuclear Medicine, Vol. 57, Issue 12
  • DOI: 10.2967/jnumed.116.178673

Production of α-particle emitting 211 At using 45 MeV α-beam
journal, May 2014


Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
journal, March 2015


Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
journal, September 2011

  • Allen, Barry J.; Singla, Apresh A.; Rizvi, Syed M. Abbas
  • Immunotherapy, Vol. 3, Issue 9
  • DOI: 10.2217/imt.11.97

Enhanced Loading Efficiency and Retention of 225 Ac in Rigid Liposomes for Potential Targeted Therapy of Micrometastases
journal, June 2008

  • Chang, Min-Yuan; Seideman, Jonathan; Sofou, Stavroula
  • Bioconjugate Chemistry, Vol. 19, Issue 6
  • DOI: 10.1021/bc700440a

Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes
journal, July 2007

  • McDevitt, M. R.; Chattopadhyay, D.; Kappel, B. J.
  • Journal of Nuclear Medicine, Vol. 48, Issue 7
  • DOI: 10.2967/jnumed.106.039131

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
journal, February 2016


An overview of targeted alpha therapy
journal, December 2011


Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields
journal, August 2001


(2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted  -Particle Radiopharmaceutical Therapy
journal, May 2016


Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction
journal, February 1996

  • Larsen, Roy H.; Wieland, Bruce W.; Zalutsky, Michael R.
  • Applied Radiation and Isotopes, Vol. 47, Issue 2
  • DOI: 10.1016/0969-8043(95)00285-5

α-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212 Pb-Labeled Radioimmunoconjugate Targeting HER2
journal, October 2005

  • Milenic, Diane E.; Garmestani, Kayhan; Brady, Erik D.
  • Cancer Biotherapy and Radiopharmaceuticals, Vol. 20, Issue 5
  • DOI: 10.1089/cbr.2005.20.557

Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies
journal, October 2007


What is the Role of the Bystander Response in Radionuclide Therapies?
journal, January 2013


Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers
journal, October 2004


Radioimmunotherapy with alpha-emitting nuclides
journal, September 1998

  • McDevitt, Michael R.; Sgouros, George; Finn, Ronald D.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 25, Issue 9
  • DOI: 10.1007/s002590050306

Modification of Radiation Damage by Fractionation of the Dose, Anoxia, and Chemical Protectors in Relation to let
journal, March 1964


LaPO 4 Nanoparticles Doped with Actinium-225 that Partially Sequester Daughter Radionuclides
journal, April 2011

  • Woodward, Jonathan; Kennel, Stephen J.; Stuckey, Alan
  • Bioconjugate Chemistry, Vol. 22, Issue 4
  • DOI: 10.1021/bc100574f

The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
journal, January 2016


Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab
journal, January 2018

  • Meredith, Ruby F.; Torgue, Julien J.; Rozgaja, Tania A.
  • American Journal of Clinical Oncology, Vol. 41, Issue 7
  • DOI: 10.1097/COC.0000000000000353

Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200MeV
journal, November 2012


Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers
journal, November 2007

  • Sofou, Stavroula; Kappel, Barry J.; Jaggi, Jaspreet S.
  • Bioconjugate Chemistry, Vol. 18, Issue 6
  • DOI: 10.1021/bc070075t

Bystander effects and radiotherapy
journal, January 2015

  • Marín, Alicia; Martín, Margarita; Liñán, Olga
  • Reports of Practical Oncology & Radiotherapy, Vol. 20, Issue 1
  • DOI: 10.1016/j.rpor.2014.08.004

Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy
journal, November 2015


Targeting of Radio-Isotopes for Cancer Therapy
journal, April 2004

  • Milenic, Diane E.; Brechbiel, Martin W.
  • Cancer Biology & Therapy, Vol. 3, Issue 4
  • DOI: 10.4161/cbt.3.4.790

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
journal, February 2010

  • Cordier, D.; Forrer, F.; Bruchertseifer, F.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 7
  • DOI: 10.1007/s00259-010-1385-5

Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223
journal, March 2016


Targeted Alpha Therapy with 213Bi
journal, October 2011

  • Morgenstern, Alfred; Bruchertseifer, Frank; Apostolidis, Christos
  • Current Radiopharmaceuticalse, Vol. 4, Issue 4
  • DOI: 10.2174/1874471011104040295

Pharmacokinetics and Imaging of 212 Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
journal, February 2014

  • Meredith, Ruby F.; Torgue, Julien; Azure, Michael T.
  • Cancer Biotherapy and Radiopharmaceuticals, Vol. 29, Issue 1
  • DOI: 10.1089/cbr.2013.1531

The Metabolism of Actinium in the Rat
journal, January 1970


213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
journal, March 2017

  • Sathekge, Mike; Knoesen, Otto; Meckel, Marian
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, Issue 6
  • DOI: 10.1007/s00259-017-3657-9

Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
journal, November 2015

  • Cederkrantz, Elin; Andersson, Håkan; Bernhardt, Peter
  • International Journal of Radiation Oncology*Biology*Physics, Vol. 93, Issue 3
  • DOI: 10.1016/j.ijrobp.2015.07.005

A new internal target system for production of 211At on the cyclotron U-120M
journal, July 2005


B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models
journal, April 2017


Production of 211 At by a vertical beam irradiation method
journal, December 2014


Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors
journal, January 2009

  • Chatal, Jean-Francois; Davodeau, Francois; Cherel, Michel
  • Journal of Cancer Research and Therapeutics, Vol. 5, Issue 9
  • DOI: 10.4103/0973-1482.55139

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
journal, July 2014

  • Kratochwil, C.; Giesel, F. L.; Bruchertseifer, F.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Issue 11
  • DOI: 10.1007/s00259-014-2857-9

Renal Tubulointerstitial Changes after Internal Irradiation with α-Particle–Emitting Actinium Daughters
journal, June 2005

  • Jaggi, Jaspreet Singh; Seshan, Surya V.; McDevitt, Michael R.
  • Journal of the American Society of Nephrology, Vol. 16, Issue 9
  • DOI: 10.1681/ASN.2004110945

Metabolic Characteristics Within a Chemical Family
journal, January 1959


Intraperitoneal  -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
journal, June 2009


A kit method for the high level synthesis of [211At]MABG
journal, May 2007

  • Vaidyanathan, Ganesan; Affleck, Donna J.; Alston, Kevin L.
  • Bioorganic & Medicinal Chemistry, Vol. 15, Issue 10
  • DOI: 10.1016/j.bmc.2007.03.016

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of  -Particle Emitters for Targeted Radionuclide Therapy
journal, January 2010


Intralesional targeted alpha therapy for metastatic melanoma
journal, December 2005

  • Allen, Barry J.; Raja, Chand; Rizvi, Syed
  • Cancer Biology & Therapy, Vol. 4, Issue 12
  • DOI: 10.4161/cbt.4.12.2251

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
journal, November 2013


Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
journal, November 2010


Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
journal, September 2010


Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
journal, April 2006

  • Jaggi, Jaspreet Singh; Seshan, Surya V.; McDevitt, Michael R.
  • International Journal of Radiation Oncology*Biology*Physics, Vol. 64, Issue 5
  • DOI: 10.1016/j.ijrobp.2005.11.036

Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters
journal, September 2001

  • Hamacher, K. A.; Sgouros, G.
  • Medical Physics, Vol. 28, Issue 9
  • DOI: 10.1118/1.1395026

Improved tumor imaging and therapy via i.v. IgG–mediated time-sequential modulation of neonatal Fc receptor
journal, September 2007

  • Singh Jaggi, Jaspreet; Carrasquillo, Jorge A.; Seshan, Surya V.
  • Journal of Clinical Investigation, Vol. 117, Issue 9
  • DOI: 10.1172/JCI32226

Melanoma Therapy via Peptide-Targeted  -Radiation
journal, August 2005


Large scale accelerator production of 225Ac: Effective cross sections for 78–192 MeV protons incident on 232Th targets
journal, December 2016


Radioimmunotherapy of Breast Cancer Metastases with  -Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
journal, November 2009


The Relative Radiosensitivity of the Nucleus and Cytoplasm of Chinese Hamster Fibroblasts
journal, June 1970


Breaking Chemoresistance and Radioresistance with [ 213 Bi]anti-CD45 Antibodies in Leukemia Cells
journal, March 2007


Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma
journal, June 2007

  • Raja, Chand; Graham, Peter; Rizvi, Syed
  • Cancer Biology & Therapy, Vol. 6, Issue 6
  • DOI: 10.4161/cbt.6.6.4089

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation
journal, May 1999

  • McDevitt, Michael R.; Finn, Ronald D.; Sgouros, George
  • Applied Radiation and Isotopes, Vol. 50, Issue 5, p. 895-904
  • DOI: 10.1016/S0969-8043(98)00151-1

Evaluation of 225 Ac for Vascular Targeted Radioimmunotherapy of Lung Tumors
journal, June 2000

  • Kennel, Stephen J.; Chappell, Lara L.; Dadachova, Kate
  • Cancer Biotherapy and Radiopharmaceuticals, Vol. 15, Issue 3
  • DOI: 10.1089/108497800414329

Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer
journal, June 2007

  • Song, Emma Y.; Rizvi, Syed M. A.; Qu, Chang F.
  • Cancer Biology & Therapy, Vol. 6, Issue 6
  • DOI: 10.4161/cbt.6.6.4097

New insights on cell death from radiation exposure
journal, July 2005


Astatine-211: Production and Availability
journal, July 2011


Remodeling the Vascular Microenvironment of Glioblastoma with  -Particles
journal, June 2016

  • Behling, K.; Maguire, W. F.; Di Gialleonardo, V.
  • Journal of Nuclear Medicine, Vol. 57, Issue 11
  • DOI: 10.2967/jnumed.116.173559

Efforts to Control the Errant Products of a Targeted In vivo Generator
journal, June 2005


Long-Term Toxicity of 213Bi-Labelled BSA in Mice
journal, March 2016


Cytotoxicity of 213Bi- and 225Ac-immunoconjugates
journal, January 1995


    Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.